KINDSTAR GLOBAL (09960) following investment, molecular diagnostics company Tourejing gets 50 million angel round investment.

Recently, Wuhan Torojing Medical Technology Co., Ltd. (referred to as "Torojing") received a 30 million yuan angel investment led by Ruijiang Kangsheng Phase II Fund from Ruijiang Investment Management, with an additional 20 million yuan investment from KINDSTAR GLOBAL (09960) investment company, totaling 50 million yuan in angel investment. This investment will assist Torojing in technology transformation, product development, and global market expansion in high-end medical devices. Wuhan Torojing (ToBio, Inc) is a global molecular diagnostics company with technology innovation at its core, founded by top international scholars and senior experts in the Chinese diagnostics industry. The company is headquartered in Wuhan, with R&D centers in Boston and Shanghai, focusing on the development of ultra-multiple diagnostic technology platforms and molecular companion diagnostics (POCT) technology, with several revolutionary international patents. Its ultra-multiple polymerase chain reaction (PCR) testing equipment can complete testing for up to thousands of targets in 15 to 30 minutes and produce reports. Compared to mainstream real-time fluorescent quantitative PCR (qPCR) technology, its innovative ultra-multiple PCR technology has outstanding advantages such as higher target coverage, faster detection speed, and the ability to develop customized reaction cartridges, filling the gap between qPCR and high-throughput sequencing technology platforms. Wuhan Torojing's ultra-multiple PCR equipment and supporting reagent products can quickly achieve market conversion, promoting their application in the fields of infection, cancer, genetic diseases, and more. In the future, this technology will effectively address the limitations of traditional multiple PCR testing in terms of target quantity and the high cost and complexity of second-generation sequencing, making molecular diagnostics more accessible. Yao Zhengxiong, General Manager of Torojing, said, "The POCT molecular diagnostics market is developing rapidly in China, and ultra-multiple PCR technology is expected to become a new benchmark in the industry. The establishment of Torojing will lead the transformation of the domestic molecular diagnostics industry. The joint investment of Ruijiang and KINDSTAR GLOBAL will create a synergy of 'capital + industry' to accelerate Torojing's technological research and market expansion." Professor Huang Shi'ang, founder and CEO of KINDSTAR GLOBAL, said, "As an important component of modern medical field, molecular diagnostic technology has high accuracy and efficiency. We believe that it will maintain rapid growth in the next few years and usher in opportunities for comprehensive development. We are pleased to cooperate with Ruijiang Fund in this investment in Torojing project. The company's products will target both domestic and international markets, aiming to promote the innovation of ultra-multiple PCR testing technology, accurately address key pain points in clinical medicine, reduce testing costs through technological innovation, and benefit society and patients."